Heron Therapeutics
Heron Therapeutics, headquartered in San Diego, California, develops therapies for acute and oncology care, with a product portfolio that includes SUSTOL®, CINVANTI®, ZYNRELEF®, and APONVIE™.
Company Overview
Heron Therapeutics is a biopharmaceutical company focused on developing therapies for acute care and oncology care. Headquartered in San Diego, California, the company is dedicated to improving the lives of patients by developing best-in-class medicines that address unmet medical needs. Heron Therapeutics applies innovative science and technologies to already-approved pharmacological agents to develop novel, patient-focused solutions. The company uses its proprietary Biochronomer® drug delivery technology to deliver therapeutic levels of pharmacological agents over a longer period with a single injection or application.
Product Portfolio
Heron Therapeutics has a diverse product portfolio that includes SUSTOL®, CINVANTI®, ZYNRELEF®, and APONVIE™. SUSTOL® is a serotonin-3 (5-HT3) receptor antagonist approved by the U.S. FDA for preventing acute and delayed nausea and vomiting associated with chemotherapy. CINVANTI® is a substance P/neurokinin-1 (NK1) receptor antagonist approved by the FDA for the prevention of chemotherapy-related nausea and vomiting. ZYNRELEF® is an extended-release local anesthetic used for postoperative pain management in several countries including the U.S., Canada, and 31 European countries. APONVIE™ is another NK1 receptor antagonist, approved by the FDA for postoperative nausea and vomiting.
Innovative Technologies
Heron Therapeutics leverages advanced scientific principles and patented technologies to enhance drug discovery and development. The company's proprietary Biochronomer® drug delivery technology allows for the controlled release of therapeutic agents, providing consistent treatment outcomes with a single application or injection. This innovative approach helps in developing better-tolerated and more effective patient care solutions.
Regulatory Approvals and Market Reach
Heron Therapeutics' ZYNRELEF® initially received FDA approval in May 2021 and has since expanded its indications for use. ZYNRELEF® has also been granted marketing authorization by the European Commission and the United Kingdom Regulatory Authority, although the company has cancelled these authorizations as of 2023. The company’s products, like CINVANTI® and APONVIE™, are designed with patient convenience in mind, offering options like 2-minute IV injections or 30-second intravenous infusions.
Employee Benefits and Community Involvement
Heron Therapeutics offers a comprehensive benefits package to its employees, including medical plans, matching 401(k) contributions, and an employee stock purchase plan. The company is also committed to supporting programs and activities related to oncology, supportive care oncology, postoperative pain management, and reducing opioid dependence. Heron Therapeutics provides funding for Investigator-Initiated Trials, Medical Educational Grants, Sponsorships, and Charitable Contributions.